Replies to post #182195 on Biotech Values

[DewDiligence]

Clinical / Regulatory / Litigation Calendar

[Please keep these entries up to date! See
the updating procedure at the end of this post.
Items that are out of date will be removed.]

NOTE: ANYONE MAY UPDATE THIS FILE


Edits: ABBV/ENTA, GILD, PFE.


ABBV—HCV program: see ENTA.

ENTA/ABBV—3-DAA HCV regimen: PDUFA date 12/21/14; EMA decision on MAA expected 1H15 (MAA submitted 5/8/14).

ENTA/ABBV—ABT-493/ABT-530 2-DAA regimen: ENTA decision whether to opt in for US profit sharing is overdue, but the decision may already have been made (http://investorshub.advfn.com/boards/read_msg.aspx?message_id=107024841 ).

GILD—Harvoni in EU: approved by CHMP 9/26/14, awaiting rubber-stamping by EU Commission. (Approved by FDA 10/10/14.)

GILD—Stribild-TAF (i.e. Stribild with TAF substituted for Viread): NDA/MAA submissions 4Q14.

MNTA—See http://investorshub.advfn.com/boards/read_msg.aspx?message_id=104928571

MRK—Keytrada (pembrolizumab) in melanoma: EU MAA accepted for review 6/30/14—EU approval possible in 1H15. (Approved by FDA 9/4/14.)

PFE—Palbociclib AA NDA in breast cancer: PDUFA date 4/13/15.

XOMA—EYEGUARD-B ph3 in Behçet’s uveitis: top-line data 2H14.

--
Procedure for Updating Calendar

When adding or modifying entries, please follow these steps:

1. Copy the complete text from the old calendar.

2. Make your additions or modifications, inserting new items in alphabetical order.

3. Near the top of the message, list the ticker symbols of the entries you changed (e.g. “Edits: GILD MNTA”).